Back to top
more

Assertio (ASRT)

(Real Time Quote from BATS)

$0.72 USD

0.72
121,182

+0.01 (1.05%)

Updated Aug 4, 2025 02:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Axsome (AXSM) to Acquire Jazz's Sleep Disorder Drug, Sunosi

by Zacks Equity Research

Axsome (AXSM) inks an agreement with Jazz Pharmaceuticals to acquire the latter's new sleep disorder drug, Sunosi. The transaction is expected to close in the second quarter of 2022.

Zacks Equity Research

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.

Zacks Equity Research

JAZZ Initiates Zepzelca Basket Study in Advanced Solid Tumors

by Zacks Equity Research

JAZZ enrolls the first patient in a mid-stage study to evaluate its lung cancer drug, Zepzelca, in advanced and difficult-to-treat cancer indications in previously-treated patients.

Zacks Equity Research

New Strong Buy Stocks for March 24th

by Zacks Equity Research

ASRT, CPRI, GRIN, OCDX, and KN have been added to the Zacks Rank #1 (Strong Buy) List on March 24, 2022.

Zacks Equity Research

Are Investors Undervaluing These Medical Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

New Strong Buy Stocks for March 15th

by Zacks Equity Research

CPRI, GOGL, EOG, ASRT, and IMO have been added to the Zacks Rank #1 (Strong Buy) List on March 15, 2022.

Zacks Equity Research

The Zacks Analyst Blog Highlights USA Truck, TimkenSteel, JAKKS Pacific, United Fire Group, and Assertio Holdings

by Zacks Equity Research

USA Truck, TimkenSteel, JAKKS Pacific, United Fire Group, and Assertio Holdings are included in today's Analyst blog.

Zacks Equity Research

Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B

by Zacks Equity Research

Bayer (BAYRY) to sell off its Environmental Science Professional business unit to Cinven for $2.6 billion. The company plans to focus on core agricultural businesses.

Zacks Equity Research

Allogene's (ALLO) CAR T Therapy Gets Fast Track Designation

by Zacks Equity Research

The FDA grants a Fast Track designation to Allogene's (ALLO) early-stage CAR T therapy candidate, ALLO-316, for treating advanced or metastatic clear cell RCC.

Nalak Das headshot

Top 5 High-Flying Small Hidden Gems Amid Wall Street Mayhem

by Nalak Das

We have narrowed our search to five small-cap stocks that have provided double-digit returns year to date. These are: USAK, TMST, JAKK, UFCS and ASRT.

Zacks Equity Research

Bayer (BAYRY) Files for Nubeqa's Label Expansion in US & EU

by Zacks Equity Research

Bayer (BAYRY) submits regulatory applications to the FDA and the EMA, seeking approval for a new indication of Nubeqa for treating metastatic hormone-sensitive prostate cancer.

Zacks Equity Research

Is Liquidia Technologies, Inc. (LQDA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.

Zacks Equity Research

Assertio (ASRT) Q4 Earnings Lag Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -16.67% and 8.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics

by Zacks Equity Research

Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics have been highlighted in this Industry Outlook article.

Zacks Equity Research

Amarin (AMRN) Q4 Earnings Top, Sales Hurt by Vascepa Generics

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales decline amid rising generic competition and COVID-19 related disruptions during the fourth quarter. The company's stock falls on Mar 1, following the earnings release.

Zacks Equity Research

Sarepta (SRPT) Q4 Earnings Beat, DMD Drugs Sales Robust

by Zacks Equity Research

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the fourth quarter. The company also raises revenue guidance for the year. Stock down in after-market trading.

Zacks Equity Research

JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs

by Zacks Equity Research

JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

Kinjel Shah headshot

4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry

by Kinjel Shah

Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.

Zacks Equity Research

Perrigo (PRGO) Q4 Earnings Beat as Cough & Cold Sales Recover

by Zacks Equity Research

Perrigo (PRGO) reports encouraging fourth-quarter 2021 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Stock gains.

Zacks Equity Research

Assertio (ASRT) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

Assertio (ASRT) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Homology Medicines (FIXX) have performed compared to their sector so far this year.

Zacks Equity Research

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 31.58% and 139.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Zacks Equity Research

Despite Fast-paced Momentum, Assertio (ASRT) Is Still a Bargain Stock

by Zacks Equity Research

Assertio (ASRT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Is Accuray (ARAY) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Accuray (ARAY) and Assertio (ASRT) have performed compared to their sector so far this year.